Related Experiment Videos
Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study
M E Weinblatt1, H Kaplan, B F Germain
1Brigham and Women's Hospital, Boston, Massachusetts 02115.
Arthritis and Rheumatism
|October 1, 1994
Summary
Long-term oral methotrexate (MTX) significantly improved rheumatoid arthritis (RA) symptoms and function over 5 years. Most patients maintained treatment with acceptable tolerability, demonstrating sustained efficacy.
Area of Science:
- Rheumatology
- Clinical Pharmacology
- Immunology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring long-term management.
- Oral methotrexate (MTX) is a common treatment for RA, but long-term efficacy and tolerability data are crucial.
Purpose of the Study:
- To assess the long-term (5-year) efficacy and tolerability of oral methotrexate in patients with rheumatoid arthritis.
- To evaluate sustained clinical response and functional status improvements with continuous MTX treatment.
Main Methods:
- A 5-year prospective study involving 123 patients with RA who previously completed a 9-month trial.
- Patients continued treatment with oral methotrexate (MTX).
- Clinical disease variables, functional status, and Westergren erythrocyte sedimentation rate (ESR) were monitored.
Main Results:
- Significant improvements were observed in clinical disease variables, functional status, and ESR (P = 0.0001) compared to baseline.
- Marked improvement in joint pain/tenderness (71%) and swelling (69%) was noted.
- 64% of patients completed the 5-year study while on MTX, with an acceptable toxicity profile.
Conclusions:
- Long-term oral MTX treatment in RA demonstrates sustained clinical efficacy and functional improvement.
- The Westergren ESR also showed sustained improvement.
- The study confirms an acceptable toxicity profile for long-term oral MTX use in RA management.